Filing Details

Accession Number:
0001415889-24-000818
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-01-08 18:00:20
Reporting Period:
2024-01-05
Accepted Time:
2024-01-08 18:00:20
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1798749 Aerovate Therapeutics Inc. AVTE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1168060 Ralph Niven C/O Aerovate Therapeutics, Inc.
930 Winter Street, Suite M-500
Waltham MA 02451
Chief Scientific Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-01-05 1,400 $1.74 3,009 No 4 M Direct
Common Stock Acquisiton 2024-01-05 3,200 $2.14 6,209 No 4 M Direct
Common Stock Disposition 2024-01-05 2,126 $18.67 4,083 No 4 S Direct
Common Stock Disposition 2024-01-05 2,474 $19.57 1,609 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2024-01-05 900 $0.00 900 $1.74
Common Stock Stock Option (Right to Buy) Disposition 2024-01-05 500 $0.00 500 $1.74
Common Stock Stock Option (Right to Buy) Disposition 2024-01-05 500 $0.00 500 $2.14
Common Stock Stock Option (Right to Buy) Disposition 2024-01-05 1,200 $0.00 1,200 $2.14
Common Stock Stock Option (Right to Buy) Disposition 2024-01-05 1,500 $0.00 1,500 $2.14
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
14,208 2030-09-03 No 4 M Direct
9,588 2030-09-03 No 4 M Direct
11,394 2031-04-01 No 4 M Direct
36,108 2031-04-01 No 4 M Direct
43,232 2031-04-01 No 4 M Direct
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023.
  2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.315 to $19.30, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
  3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.375 to $19.88, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request
  4. A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
  5. A total of 14,488 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on June 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
  6. A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on May 2, 2021.
  7. A total of 49,908 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021.
  8. A total of 59,732 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021.